What is Grifols SA ADR?
operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 8.78B, and a P/E ratio of 20.2x.
A short list of Drug Manufacturers - General names that are close enough in size to make side-by-side comparison useful.